Last €48.58 EUR
Change Today -1.17 / -2.36%
Volume 3.6K
BRM On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 3:14 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€49.91
Previous Close
€49.76
Day High
€52.03
Day Low
€48.28
52 Week High
12/23/14 - €52.03
52 Week Low
06/10/14 - €34.12
Market Cap
80.6B
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
12/30/14
P/E TM
--
Dividend
€1.48
Dividend Yield
2.20%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $843.1K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BRM) Key Developments

Bristol-Myers Squibb Company and Pfizer Announce Positive Results from Anticoagulant Study

Bristol-Myers Squibb Company and Pfizer Inc. have announced results from a human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates, or PCCs, in healthy subjects. The study results demonstrated that both PCCs, Sanquin's Cofact (a heparin-free formulation) and CSL Behring's Beriplex P/N (a formulation containing heparin) reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential (ETP). Eliquis is a novel oral anticoagulant that specifically inhibits Factor Xa. This study evaluated the effect of two non-activated 4-factor PCCs, Cofact and Beriplex P/N, on Eliquis pharmacodynamics and pharmacokinetics in healthy subjects. Cofact and Beriplex P/N are used to stop severe bleeding in patients taking vitamin K antagonists, such as warfarin, or with a blood clotting factor deficiency. Currently there are no approved reversal agents for Eliquis or other direct Factor Xa inhibitors. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects (mean age 33+7 years). Within each period, subjects received Eliquis 10 mg twice daily. On day four (after steady-state was achieved), three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. The mean Eliquis pharmacokinetic profiles were consistent across all treatment groups and were not affected by PCC administration. Following completion of the 30-minute Cofact infusion, the effect of Eliquis on ETP was significantly reduced compared to placebo (p 0.05). Mean ETP was comparable to the day four Eliquis pre-dose value (steady-state trough Eliquis concentration) at the end of the Cofact infusion and 30 minutes after completing the Beriplex P/N infusion. Mean ETP was within the baseline value (Eliquis naive) within 5.5 hours after completing the infusion for both PCCs. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.

Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Metastatic melanoma is the deadliest form of skin cancer, and despite recent advances, there are limited treatment options available for patients who have been previously treated with approved agents.

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announces Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Ono Pharmaceutical Co.,Ltd. Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors. Opdivo, launched in Japan in September 2014 for the treatment of patients with unresectable melanoma, is being developed in multiple tumor types in more than 50 clinical trials worldwide. Mogamulizumab was launched in Japan in May 2012 for the treatment of relapsed or refractory CCR4-positive Adult T-cell Leukemia-Lymphoma (ATL), and granted the indication expansion in March 2014 for relapsed or refractory CCR4-positive Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Clinical trials with mogamulizumab in ATL, PTCL, and CTCL are ongoing in the U.S., European Union (EU) and other countries. Opdivo and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Opdivo binds to the checkpoint receptor PD-1 expressed on activated T-cells, blocking this pathway and enabling the immune system to attack tumors, while mogamulizumab can suppress some of the immune cells that shield the tumor from the immune system. Pre-clinical evidence for each therapy suggests the combination of Opdivo and mogamulizumab may lead to an enhanced anti-tumor immune response compared to either agent alone.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €48.58 EUR -1.17

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.98 USD +0.77
Actavis plc $257.09 USD +2.89
Biogen Idec Inc $342.40 USD +1.51
Celgene Corp $113.35 USD +3.75
Novo Nordisk A/S kr260.80 DKK -6.40
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 36.3x
Price/Sales 6.1x
Price/Book 6.5x
Price/Cash Flow 36.1x
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.